Economic evaluations of gastric and pancreatic cancer

Hepato-Gastroenterology

Volumn 46, Issue 26, 1999, Pages 1206-1213

  Elixhauser, Anne ^a   Halpern, Michael T ^b  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Cost of illness; Cost benefit analysis; Cost effectiveness analysis; Gastric cancer; Pancreatic cancer or neoplasm; Stomach neoplasm

Indexed keywords

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; UNITED STATES;

COST OF ILLNESS; COSTS AND COST ANALYSIS; HUMANS; PANCREATIC NEOPLASMS; PATIENT CARE TEAM; STOMACH NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 0032905133     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. 1 Kosary CL, Ries LAG, Miller BA, Hankey BF, Harra A, Edwards BK (Eds.): SEER Cancer Statistics Review, 1973-1992: Tables and Graphs, National Cancer Institute. NIH Publication No. 96-2789. Bethesda MD, 1996.
2. 2 Brown DM, Everhart JE: Cost of digestive disease in the United States. In: Everhart JE (Ed.). Digestive Disease in the United States: Epidemiology and Impact. U.S. Department of Health and Human Services. National Institutes of Health, 1994.
3. 3 Brown ML: The national economic burden of cancer: an update. J Natl Cancer Inst 1990; 82:1811-1814.
4. 4 American Cancer Society: Cancer facts and figures. New York, American Cancer Society, 1997.
5. 5 Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, Sjoden PO: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Annals of Oncology 1995; 6:267-274.
6. 6 Edge SB, Schmieg RE, Rosenlof LK, Wilherlm MC: Pancreas cancer resection outcome in American University Centers in 1989-1990. Cancer 1993; 71:3502-3508.
7. 7 Holbrook RF, Hargrave K, Traverso W: A prospective cost analysis of pancreatoduodenectomy. Am J Surg 1996; 171:508-511.
8. 8 Patel AG, Toyama MT, Kusske AM, Alexander P, Ashley SW, Reber HA: Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg 1995; 130(8):838-842.
9. 9 Gudjonsson B: Carcinoma of the pancreas: critical analysis of costs, results of resections and the need for standardized reporting. J Am Coll Surg 1995; 181:483-503.
10. 10 Lea MS, Stahlgren LH: Is resection appropriate for adenocarcinoma of the pancreas? A cost-benefit analysis. Am J Surg 1987; 154:651-654.
11. 11 Graadal O, Schlichting E, Aasen AO, Stadaas JO: Use of resource in the treatment of pancreatic cancer. Tidsskr Nor Laegeforen 1990; 110:2981-2982. (In Norwegian with English abstract)
12. 12 Brandabur JJ, Kozarek RA, Ball TJ, Hofer BO, Ryan JA, Traverso LW, Freeny PC, Lewis GP: Nonoperative versus operative treatment of obstructive jaundice in pancreatic cancer: cost and survival analysis. Am J Gastroenterol 1988; 83:1132-1139.
13. 13 Raikar GV, Melin MM, Ress A, Lettieri SZ, Poterucha JJ, Nagorney DM, Donohue JH: Cost-effective analysis of surgical palliation versus endoscopie stenting in the management of unresectable pancreatic cancer. Annals of Surgical Oncology 1996; 3:470-475.
14. 14 Clark CG, Boulos PB, Ward MWN: Cost effectiveness in the treatment of gastric cancer. Clinical Oncology 1980; 6:303-307.
15. 15 Walsh TH: Audit of outcome of major surgery in the elderly. British Journal of Surgery 1996; 83:92-97.
16. 16 Smith TJ, Grisso G, Hillner BE, Desch CE: An estimate of the efficacy and cost effectiveness of chemotherapy for metastatic gastric carcinoma. Proc Annu Meet Am Soc Clin Oncol 1992; 11:A533. (Meeting abstract)
17. 17 Norum J, Angelsen V: Chemotherapy in gastric cancer: An economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. J Chemother 1995; 7:455-459.
18. 18 Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe, JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-267.
19. 19 D'Amico D, Bassi N, Ranzato R: Cost-benefit of follow-up after total gastrectomy. Hepato-Gastroenterol 1989; 36:266-272.
20. 20 Lacueva FJ, Calpena R, Medrano J, Compan AF, Andrada E, Molto M, Ferrer R, Diego M: Follow-up of patients resected for gastric cancer. J Surg Oncol 1995; 60:174-179.